Axsome Therapeutics (NASDAQ:AXSM) Director Susan Mahony Sells 300 Shares of Stock

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Susan Mahony sold 300 shares of the business’s stock in a transaction dated Tuesday, June 9th. The stock was sold at an average price of $237.21, for a total value of $71,163.00. Following the transaction, the director owned 1,129 shares in the company, valued at approximately $267,810.09. This represents a 20.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Axsome Therapeutics Trading Up 0.3%

Shares of AXSM opened at $246.34 on Thursday. The stock’s 50-day moving average is $207.58 and its two-hundred day moving average is $180.70. The stock has a market cap of $12.68 billion, a PE ratio of -66.04 and a beta of 0.61. Axsome Therapeutics, Inc. has a 12 month low of $96.09 and a 12 month high of $256.00. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, May 4th. The company reported ($1.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.41). The company had revenue of $191.20 million for the quarter, compared to analyst estimates of $191.10 million. Axsome Therapeutics had a negative return on equity of 267.16% and a negative net margin of 26.59%.The business’s revenue was up 57.4% compared to the same quarter last year. Equities analysts forecast that Axsome Therapeutics, Inc. will post -2.24 earnings per share for the current fiscal year.

Analyst Ratings Changes

AXSM has been the topic of several recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $272.00 price target on shares of Axsome Therapeutics in a research note on Monday, May 4th. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Friday, May 1st. Piper Sandler reiterated an “overweight” rating and issued a $258.00 price target on shares of Axsome Therapeutics in a research note on Monday, May 4th. Oppenheimer set a $280.00 price target on Axsome Therapeutics in a research note on Monday, May 4th. Finally, Robert W. Baird boosted their price target on Axsome Therapeutics from $241.00 to $246.00 and gave the stock an “outperform” rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Axsome Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $251.26.

Institutional Trading of Axsome Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of AXSM. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Axsome Therapeutics by 4.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after buying an additional 1,002 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in Axsome Therapeutics by 2,407.9% in the first quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after buying an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after buying an additional 84,151 shares during the last quarter. Caxton Associates LLP bought a new stake in Axsome Therapeutics in the first quarter valued at about $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Axsome Therapeutics by 29.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock valued at $8,735,000 after buying an additional 17,250 shares during the last quarter. 81.49% of the stock is owned by institutional investors.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.